Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Preferred Stock Liabilities (2018 - 2019)

10x Genomics' Preferred Stock Liabilities history spans 2 years, with the latest figure at $243.2 million for Q2 2019.

  • For Q2 2019, Preferred Stock Liabilities changed N/A year-over-year to $243.2 million; the TTM value through Jun 2019 reached $243.2 million, changed N/A, while the annual FY2018 figure was $243.2 million, 53.55% up from the prior year.
  • Preferred Stock Liabilities for Q2 2019 was $243.2 million at 10x Genomics, roughly flat from $243.2 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $243.2 million in Q4 2018 and bottomed at $208.3 million in Q3 2018.